COMPANY

Promontory Therapeutics

HQ: New York, NY source · promontorytx.com ↗

Keywords: small molecule oncology PT-112 mCRPC Metastatic Castrate-resistant Prostate Cancer Prostatic Neoplasms Male Genital Neoplasms Urogenital Neoplasms Neoplasms by Site Non-Small Cell Lung Cancer Multiple Myeloma

Location: New York, NY · source · Oct 15, 2026

Profile checked Oct 10, 2026

3Trials (company is sponsor)

Timeline

Apr 24, 2018 Trial start Phase 1/Phase 2: A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab source ↗
Dec 15, 2017 Trial start 1: A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma source ↗
2014-07 Trial start Phase 2: A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohor source ↗

Clinical trials (lead sponsor) 3

Record	Title	Phase	Status	Start	Primary completion
NCT02266745	A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts	Phase 2	Unknown status (ClinicalTrials.gov)	2014-07	Aug 1, 2024 (estimated)
NCT03409458	A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab	Phase 1/Phase 2	Completed	Apr 24, 2018	Jun 1, 2022 (actual)
NCT03288480	A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma	1	Completed	Dec 15, 2017	Sep 30, 2020 (actual)